Evolution of the Average Target: Ocular Therapeutix, Inc.

Evolution of the Target Price: Ocular Therapeutix, Inc.

Changes in Analyst Recommendations: Ocular Therapeutix, Inc.

4.IMEXLCYFNgllw_6c9dGyWtrnNj5SU-fuKHCAiaYxqc4.VaREHx90TnEdrbDTveCFK6PUD3ckDN6ITDf06PxC3L5qsEdJSEt_OB-ntw~289e2b8e98fa99a5b57e0f141b67f6fa
06-25 Chardan Raises Price Target on Ocular Therapeutix to $23 From $21, Keeps Buy Rating MT
05-06 Ocular Therapeutix Advances FDA Talks on Single-Trial Filing for Eye Drug, RBC Says MT
12-16 RBC Capital Adjusts Ocular Therapeutix Price Target to $24 From $17, Maintains Outperform Rating MT
25-10-01 Ocular Therapeutix's Axpaxli Drug Trials for Wet AMD Poised for Success, RBC Capital Says MT
25-09-30 Ocular Therapeutix, Inc. Announces Updates Regarding Its Development Programs for AXPAXLI CI
25-09-15 Chardan Capital Initiates Ocular Therapeutix at Buy With $21 Price Target MT
25-04-08 William Blair Initiates Ocular Therapeutix With Outperform Rating MT
25-03-18 RBC Initiates Ocular Therapeutix at Outperform, Speculative Risk With $17 Price Target MT
25-03-11 Needham Initiates Ocular Therapeutix at Buy With $15 Price Target MT
24-10-16 Scotiabank Initiates Ocular Therapeutix at Sector Outperform MT
24-06-20 TD Cowen Upgrades Ocular Therapeutix to Buy From Hold, Adjusts Price Target to $11 From $7 MT
24-05-31 Piper Sandler Starts Ocular Therapeutix With Overweight Rating, $15 Price Target MT
24-03-13 HC Wainwright Adjusts Price Target on Ocular Therapeutix to $15 From $12, Keeps Buy Rating MT
24-03-12 TD Cowen Adjusts Price Target on Ocular Therapeutix to $11 From $8, Maintains Market Perform Rating MT
24-03-12 JMP Securities Adjusts Ocular Therapeutix's Price Target to $24 From $12, Maintains Market Outperform Rating MT
24-02-26 Piper Sandler Adjusts Ocular Therapeutix Price Target to $15 From $10, Maintains Overweight Rating MT
23-06-13 HC Wainwright Adjusts Ocular Therapeutix Price Target to $12 From $10, Maintains Buy Rating MT
23-05-09 HC Wainwright Adjusts Price Target on Ocular Therapeutix to $10 From $11, Maintains Buy Rating MT
23-05-09 JMP Securities Adjusts Price Target on Ocular Therapeutix to $12 From $11, Keeps Market Outperform Rating MT
23-04-21 Baird Initiates Ocular Therapeutix at Outperform With $18 Price Target MT
23-03-07 JMP Securities Adjusts Price Target on Ocular Therapeutix to $11 From $12, Maintains Market Outperform Rating MT
23-02-14 HC Wainwright Adjusts Price Target on Ocular Therapeutix to $11 From $9, Maintains Buy Rating MT
23-01-09 JMP Securities Adjusts Price Target on Ocular Therapeutix's to $12 From $25, Maintains Market Outperform Rating MT
22-11-08 Raymond James Adjusts Price Target on Ocular Therapeutix to $14 From $29, Maintains Strong Buy Rating MT
22-11-08 HC Wainwright Trims Price Target on Ocular Therapeutix to $9 From $10, Maintains Buy Rating MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+218.53%
+6.22%
+2.73%
+3.25%
+1.86%
-1.09%
+25.51%
-1.06%
-5.15%
+21.81%
Average +27.26%
Weighted average by Cap. +5.35%
See all sector consensus

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
8.505USD
Average target price
27.09USD
Spread / Average Target
+218.53%
High Price Target
34.00USD
Spread / Highest target
+299.76%
Low Price Target
18.00USD
Spread / Lowest Target
+111.64%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

Chardan Research
RBC Capital Markets
William Blair & Co.
Needham & Co.
Scotiabank
TD Cowen
Piper Sandler
HC Wainwright
JMP Securities
Baird
Raymond James
Berenberg Bank
Jefferies & Co.
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
8.505USD
Average target price
27.09USD
Spread / Average Target
+218.53%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. OCUL Stock
  4. Consensus Ocular Therapeutix, Inc.